<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053868</url>
  </required_header>
  <id_info>
    <org_study_id>19-28309</org_study_id>
    <nct_id>NCT04053868</nct_id>
  </id_info>
  <brief_title>Evaluating the Comparative Pharmacokinetics of Nicotine After Administration Via JUUL or Tobacco Cigarettes</brief_title>
  <official_title>Evaluating the Comparative Pharmacokinetics of Nicotine After Administration Via JUUL or Tobacco Cigarettes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, crossover design that will examine the pharmacokinetics and
      pharmacodynamics of impact of smoking tobacco cigarettes or vaping the JUUL electronic
      cigarette.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to better understand the pharmacokinetic and pharmacodynamics
      responses produced by the JUUL e-cigarette, compared to tobacco cigarettes, in e-cigarette
      and tobacco cigarette smokers.

      Specific Aim #1- To categorize the nicotine PK profile (maximum plasma concentration; time to
      maximum plasma concentration and area under the concentration-time curve) and compare when
      using the JUUL e-cigarette vs. a tobacco cigarette in a standardized manner.

      Specific Aim #2- To categorize the nicotine PK profile (maximum plasma concentration; time to
      maximum plasma concentration and area under the concentration-time curve) and compare when
      using the JUUL e-cigarette vs a tobacco cigarette when using the product ad libitum.

      Specific Aim #3- To evaluate various outcomes following JUUL e-cigarette or tobacco cigarette
      use, both with standardized and ad lib use including: heart rate, plasma catecholamines,
      pulmonary function testing.

      Specific Aim #4- To evaluate and compare the effects on craving, reward and satisfaction when
      using the JUUL e-cigarette vs. tobacco cigarette.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nicotine Exposure</measure>
    <time_frame>6 Hours</time_frame>
    <description>Plasma nicotine AUC (ng/ml*h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Effects: Heart Rate</measure>
    <time_frame>Hospital Days 1-2 of each Arm</time_frame>
    <description>Participant heart rate will be measured in beats per minute throughout both inpatient stays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Effects: Systolic Blood Pressure</measure>
    <time_frame>Hospital Days 1-2 of each Arm</time_frame>
    <description>Participant systolic blood pressure will be taken during e-cigarette and/or tobacco cigarette use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Effects: Diastolic Blood Pressure</measure>
    <time_frame>Hospital Days 1-2 of each Arm</time_frame>
    <description>Participant diastolic blood pressure will be taken during e-cigarette and/or tobacco cigarette use.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Nicotine Administration &amp; Dosage</condition>
  <condition>E-cigarettes</condition>
  <condition>Vaping</condition>
  <condition>E-Liquid</condition>
  <condition>Tobacco Smoking</condition>
  <arm_group>
    <arm_group_label>Electronic Cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will participate in a standardized vaping session using a JUUL E-cigarette device with a JUUL e-liquid pod.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tobacco Cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will participate in a standardized smoking session using commercial tobacco cigarettes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL</intervention_name>
    <description>Electronic Cigarette</description>
    <arm_group_label>Electronic Cigarette</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tobacco</intervention_name>
    <description>Tobacco Cigarette</description>
    <arm_group_label>Tobacco Cigarette</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy on the basis of medical history and limited physical examination, as described
             below:

          -  Heart rate &lt; 105 BPM*

          -  Systolic Blood Pressure &lt; 160 and &gt; 90*

          -  Diastolic Blood Pressure &lt; 100 and &gt; 50*

             *Considered out of range if both machine and manual readings are above/below these
             thresholds.

          -  Age: ≥ 21 &amp; ≤ 70 years old

          -  Body Mass Index ≤ 38.0 (at PI's discretion for higher BMI if no other concurrent
             health issues)

          -  Willingness to avoid combusted marijuana up to 48 hours before each study visit

          -  Nicotine strength of e-liquid of usual e-cigarette &gt; 0 mg/ml

          -  Group 1 Experienced E-cigarette users

          -  Current use of tobacco cigarettes (&lt;5 cigarettes per day)

          -  Current use an electronic cigarette device at least 15 days out of the past 30 days

          -  Group 2 Primary Tobacco cigarette users:

          -  Currently smoking ≥ 5 cigarettes per day

          -  Have tried a electronic cigarette no more than 10 times in lifetime

          -  Expired CO ≥ 8ppm

          -  Saliva cotinine ≥50 ng/ml or urine cotinine and/or NicAlert=6

        Exclusion Criteria:

          -  Medical

          -  Heart disease

          -  Seizures

          -  Cancer

          -  Thyroid disease (okay if controlled with medication)

          -  Diabetes

          -  Hepatitis B or C or Liver disease

          -  Glaucoma

          -  Kidney disease or urinary retention

          -  History of stroke

          -  An ulcer in the past year

          -  Active use of an inhaler for Asthma or COPD

          -  Psychiatric conditions

          -  Current or past schizophrenia, and/or current or past bipolar disorder

          -  Major depression, current or within the past year

          -  Major personality disorder

          -  Participants with current or past minor or moderate depression and/or anxiety
             disorders will be reviewed by the PI and/or medical monitor and considered for
             inclusion

          -  History of psychiatric hospitalizations are not exclusionary, but study participation
             will be determined as per PI's or medical monitor's approval

          -  Drug/Alcohol Dependence

          -  Alcohol or illicit drug dependence within the past 12 months with the exception of
             those who have recently completed an alcohol/drug treatment program

          -  Positive toxicology test for illicit drugs at the screening visit (THC &amp; prescribed
             medications okay)

          -  Opioid replacement therapy (including methadone, buprenorphine, or other)

          -  Psychiatric medications

          -  Current regular use of any psychiatric medications is exclusionary, with the exception
             of SSRIs and SNRIs and current evaluation by the PI and/or medical monitor that the
             participant is otherwise healthy, stable, and able to participate

          -  Medications

          -  Use of sympatholytic medications for cardiovascular conditions including hypertension
             (Example: beta and alpha-blockers)

          -  Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example:
             rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs)

          -  Concurrent use of nicotine-containing medications

          -  Any stimulant medications (example: Adderall) generally given for ADHD treatment

          -  Use of Other Tobacco Products (OTP)

          -  Any of the following products in combination more than 15 times in the past month

          -  smokeless tobacco (snus, oral snuff, chewing tobacco)

          -  pipes

          -  cigars, cigarillos, little cigars

          -  blunts, spliffs

          -  hookah

          -  Other/Misc. Chronic Health Conditions

          -  Fainting (within the last 30 days)

          -  Other &quot;life threatening illnesses&quot; as per PI's or medical monitor's discretion

          -  Pregnancy

          -  Pregnancy (self-reported and urine pregnancy test)

          -  Breastfeeding (determined by self-report)

          -  Concurrent participation in another clinical trial (at PI's discretion)

          -  Inability to read and write in English

          -  Planning to quit smoking or vaping within the next 60 days

          -  Have baseline spirometry values (FEV1, FVC, and FEV1/FVC) outside of the lower limit
             of normal as defined in NHANES III guidelines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neal L Benowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalie Nardone, PhD</last_name>
    <phone>415-514-1450</phone>
    <email>natalie.nardone@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeremy P Giberson, BS</last_name>
    <phone>415-706-6023</phone>
    <email>jeremy.giberson@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSF Tobacco Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy P Giberson, BS</last_name>
      <phone>415-706-6023</phone>
      <email>jeremy.giberson@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Nardone, PhD</last_name>
      <phone>415-514-1450</phone>
      <email>natalie.nardone@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Neal L Benowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zuckerberg San Francisco General Hospital- CTSI</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy P Giberson, BS</last_name>
      <phone>415-706-6023</phone>
      <email>jeremy.giberson@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Natalie L Nardone, PhD</last_name>
      <phone>628-206-8953</phone>
      <email>natalie.nardone@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Neal L Benowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

